(Q45401310)

14 December 2017

title

Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus (English)

1 reference

14 December 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Yuki Hashimoto

1

1 reference

14 December 2017

Hiromi Kanto

series ordinal

2

1 reference

14 December 2017

Masatoshi Itoh

series ordinal

3

1 reference

14 December 2017

publication date

1 August 2007

1 reference

The Journal of Dermatology

14 December 2017

published in

1 reference

14 December 2017

volume

34

1 reference

14 December 2017

issue

8

1 reference

14 December 2017

page(s)

577-582

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1346-8138.2007.00336.X

10.1111/J.1346-8138.2007.00336.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference